ONL logo.jpg
ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing
September 13, 2024 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., Sept. 13, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results
September 05, 2024 10:52 ET | Boehringer Ingelheim
Ingelheim, Germany and Basel, Switzerland, September 5, 2024 – Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I evaluation of BI 771716 (Study Record |...
Eclipse Logo.png
Eclipse Life Sciences Initiates Phase 2 Study for Novel Ophthalmology Steroid Implant for Diabetic Macular Edema (DME)
August 12, 2024 07:45 ET | Eclipse Life Sciences
RESEARCH TRIANGLE PARK, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company focused on the development of novel therapies...
Global Age-Related Macular Degeneration Market
Age-Related Macular Degeneration (AMD) Market Forecast Report by Disease Type, Product, Distribution Channel, Countries, and Company Analysis: 2024-2032
August 08, 2024 06:55 ET | Research and Markets
Dublin, Aug. 08, 2024 (GLOBE NEWSWIRE) -- The "Age-Related Macular Degeneration Market Forecast Report by Disease Type Product Distribution Channel Countries and Company Analysis, 2024-2032" report...
22157.jpg
Global Optometry Equipment Market Set to Reach USD 1.68 Billion by 2028
June 12, 2024 10:30 ET | Research and Markets
Dublin, June 12, 2024 (GLOBE NEWSWIRE) -- The "Global Optometry Equipment Market 2024-2028" report has been added to ResearchAndMarkets.com's offering.The global optometry equipment market is...
ONL logo.jpg
ONL Therapeutics to Present at 2024 BIO CEO & Investor Conference
February 06, 2024 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., Feb. 06, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...